Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

AstraZeneca’s listing rejig spells long-term danger for London

It’s not skipping off entirely to New York, but pharma giant sets a worrying precedent for UK stock market

The Guardian - UK

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk

The U.S. pharmaceutical industry is at the center of a policy maelstrom. President Donald Trump on Sep 25, put a 100% tariff on imported branded and patented medicines starting from Oct 1 with threats that tariffs might go up to as much as 250% in future. The instant market impact…

Benzinga

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction representing a transaction value of approximately $8 billion.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.

Benzinga

The abortion pill is safe. But why should Trump let facts get in the way?

RFK Jr is conducting a review of mifepristone, citing a deeply flawed study. The move could be devastating for women

The Guardian - US

Emma Walmsley steps down as CEO of GSK as pharmaceutical industry faces upheaval

The drug and vaccine maker is a £60bn firm – one of the biggest in the UK

The Independent UK

GSK Switches CEO As Trump Tariffs Test Pharma

British pharmaceutical giant GSK on Monday said longtime chief executive Emma Walmsley will be replaced by its chief commercial officer in January, as the company navigates US tariffs on the sector.

International Business Times

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca to upgrade US listing in ‘knock-back for London’

UK’s biggest drugmaker will put its US shares on a par with its London-based stock but says HQ will stay in Cambridge

The Guardian - UK

Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms

President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.

Benzinga

GSK’s Emma Walmsley to step down as chief executive after eight years

Chief commercial officer Luke Miels to take over as CEO at Britain’s second-biggest drugmaker

The Guardian - UK

Pfizer sued in US over contraceptive that women say caused brain tumours

US class action lawsuit alleges company failed to warn about risks of using contraceptive injection Depo-Provera

The Guardian - UK

Trump's epic economic and drug figures fizzle under scrutiny

Trump's claims on tariff revenue and decreasing drug prices clash with expert data.

Axios

NHS facing ‘critical threat’ after Trump pressure to hike drug prices

NEWS ANALYSIS: Drug prices in the UK could rise amid 100 per cent tariffs on branded medicines and pressure from US President Donald Trump to stop ‘global freeloading’, Alicja Hagopian reports

The Independent UK

The Nations And Firms Threatened By Trump's Pharma Tariffs

Donald Trump has shocked the global drug industry by announcing 100-percent tariffs on all branded, imported pharmaceutical products -- unless companies are building manufacturing plants in the United States.

International Business Times

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Trump's 100% Drug Tariffs 'A Meaningful Commercial Hit' For Americans, But 'Loopholes' Could Blunt Impact, Says Analyst

President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly Big Pharma, remains displeased.

Radio France Internationale

Calls for Covid vaccine boycott spur tensions in French pharmacy sector

As French pharmacists call for a boycott of Covid-19 vaccine orders, professional bodies and unions have issued stern warnings over the threat to public health.

The Guardian - UK

UK fuel retailers accused of ‘ripping off’ motorists at the pumps; markets shrug off latest Trump tariffs – as it happened

Rolling coverage of the latest economic and financial news

Benzinga

Moderna Stands By UK As Pharma Giants Criticize Pricing, UK Secures First Onshore mRNA Vaccine Production Centre

Moderna, Inc.‘s (NASDAQ: MRNA) UK chief Darius Hughes defended Britain's drug pricing policies after the country was branded the "worst in Europe."

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Biogen Faces FDA Setback On High-Dose Nusinersen Filing For Spinal Muscular Atrophy

On Tuesday, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for Biogen Inc.’s (NASDAQ: BIIB) supplemental New Drug Application (sNDA) for the high-dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA).

Benzinga

UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street

UniQure NV (NASDAQ: QURE) just staged one of biotech's wildest rides of the year, soaring 248% in a single session after unveiling successful trial results for its experimental Huntington's disease gene therapy. Indeed, the stock reached a 5-year high, marking its best session ever. But if you think the move…

The Independent UK

Medicine price rises ‘necessary’ to secure investments, science minister says

Major firms have already shelved or paused planned UK pharmaceutical industry investments this year.

The Guardian - UK

Moderna boss defends UK in drug-pricing row as he opens £150m Oxfordshire facility

‘We’re here to invest,’ says Darius Hughes as he calls comments by other pharma companies ‘a little harsh’

Benzinga

United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO

Eli Lilly and Co. (NYSE:LLY) CEO Dave Ricks strongly criticized the United Kingdom's approach to drug pricing, describing it as "probably the worst country in Europe" for pharmaceutical prices.

Benzinga

Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies

A U.S. federal judge has rejected challenges by two pharmaceutical manufacturers seeking to block a Maine law that regulates the use of contract pharmacies under the federal 340B drug discount program.

The Guardian - UK

UK is ‘worst country in Europe’ for drug prices, says Mounjaro maker

Eli Lilly CEO says Britain’s strict regime means it could miss out on new drugs being rolled out unless it pays more

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.